close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

aTyr Pharma, Inc. - Common Stock (NQ:ATYR)

0.7430 +0.0096 (+1.31%)
Streaming Delayed Price Updated: 11:55 AM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about aTyr Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming Deadlines – ATYR
From Pomerantz LLP
Via GlobeNewswire
News headline image
Class Action Filed Against aTyr Pharma, Inc. (ATYR) - December 8, 2025 Deadline to Join - Contact Levi & Korsinsky
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Class Action Filed Against aTyr Pharma, Inc. (ATYR) - December 8, 2025 Deadline to Join - Contact Levi &amp; Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Law Offices of Frank R. Cruz Encourages aTyr Pharma Inc. (ATYR) Shareholders To Inquire About Securities Fraud Class Action
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Law Offices of Howard G. Smith Encourages aTyr Pharma Inc. (ATYR) Shareholders To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATYR
From Pomerantz LLP
Via GlobeNewswire
News headline image
Levi & Korsinsky Notifies Shareholders of aTyr Pharma, Inc. (ATYR) of a Class Action Lawsuit and an Upcoming Deadline
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Levi &amp; Korsinsky Notifies Shareholders of aTyr Pharma, Inc. (ATYR) of a Class Action Lawsuit and an Upcoming Deadline
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Securities Fraud Investigation Into aTyr Pharma Inc. (ATYR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Faruqi & Faruqi Reminds ATyr Pharma Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 9, 2025 - ATYR
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Securities Fraud Investigation Into aTyr Pharma Inc. (ATYR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
aTyr Pharma, Inc.’s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman
From Hagens Berman
Via Business Wire
News headline image
ATYR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against aTyr Pharma, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ATYR Investor Notice: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against aTyr Pharma, Inc.
From Robbins LLP
Via GlobeNewswire
News headline image
aTyr Pharma, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR
From DJS Law Group
Via Business Wire
News headline image
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Rosen Law Firm Urges aTyr Pharma, Inc. (NASDAQ: ATYR) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of aTyr Pharma, Inc. - ATYR
From Pomerantz LLP
Via GlobeNewswire
News headline image
Benzinga Bulls And Bears: Intel, FedEx, Cracker Barrel — And Markets Close At Record Highs ↗
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
News headline image
Top 3 Health Care Stocks That May Explode In September ↗
 
Via Benzinga
News headline image
Goldman Sachs To Rally around 9%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Crude Oil Rises 1%; Manufacturing Activity in New York Falls In September ↗
 
Via Benzinga
News headline image
Which stocks are most active on Monday? ↗
Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR
From DJS Law Group
Via Business Wire
News headline image
ATyr Pharma Stock Sinks, Plans FDA Review After Mixed Phase 3 Results ↗
ATyr Pharma's stock dips after Phase 3 trial of efzofitimod misses steroid reduction goal, but shows improvements in lung function and steroid withdrawal rates. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today